JNJ
The comeback tour continues
Johnson & Johnson just dropped more lung cancer data, and the vibe is pretty simple: the company wants you to believe its oncology pair is getting harder to ignore. In the Phase 2b COPERNICUS study, subcutaneous RYBREVANT FASPRO plus LAZCLUZE showed a lower side-effect burden in patients with previously untreated advanced NSCLC carrying common EGFR mutations.
That matters because cancer drugs don’t just need to work — they need to be tolerable enough that people can actually stay on them. Here, J&J said 8% of patients stopped treatment because of adverse events, with skin rash at 25%, and both administration-related reactions and venous thromboembolism at 3%.
The real headline: people lived longer
The company also shared final overall survival results from the Phase 3 PAPILLON study, and this is the part that gets the stock-pitch eyebrows raised. Patients on intravenous RYBREVANT plus chemotherapy had a median overall survival of 34.3 months versus 27.9 months for chemo alone — more than six extra months.
Even with crossover muddying the water a bit, the prespecified analysis still pointed to a 43% drop in the risk of death. Add in progression-free survival through a second disease progression of 28.3 months versus 17.5 months, and J&J has a pretty convincing slide deck for doctors, regulators, and investors.
Why investors should care
This isn’t just biotech bingo. J&J is trying to prove its cancer franchise can keep stacking up real-world reasons for adoption:
- better efficacy
- fewer nasty side effects
- a treatment story that sounds less like punishment and more like medicine
The stock was down 0.74% when the news hit, which is basically Wall Street shrugging politely while the long game keeps playing out.
Big picture: if J&J can keep turning lung cancer data into actual physician adoption, RYBREVANT could become one of those quietly massive revenue engines that doesn’t sound sexy — until it absolutely does.